single dose of antenatal corticosteroids for pregnancies at risk of preterm delivery (snacs)

Conditions: Preterm Birth; Premature Birth; Complication of Prematurity; Obstetric Labor, Premature; Pregnancy Complications

Summary: antenatal corticosteroids (acs) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome. the standard of care for pregnant people at risk of preterm birth includes 2 doses of celestone (for a total of 24 mg in canada, or 22.8 mg in australia) to accelerate fetal lung maturity. the investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in canada, or 11.4 mg in australia) of celestone is non-inferior to the standard double doses.

preterm infants are at risk of mortality and morbidity. antenatal corticosteroids (acs) reduce the risks of neonatal death and morbidities, such as respiratory distress syndrome. the standard of care for pregnant people at risk of preterm birth includes 2 doses of celestone to accelerate fetal lung maturity (total 24 mg in canada, 22.8 mg in australia). there are no published clinical trial data on the benefits or risks of a single dose of antenatal corticosteroid vs. standard double doses (ninan et al jogc 2020). pregnant people at 22 weeks and 0 days to \< 34 weeks and 6 days' gestation at risk of preterm birth with a singleton or twin gestation who have received the first dose of celestone and consented to the trial will be randomized to receive approximately 24 hours later either an experimental placebo injection (of normal saline) or the standard double dose of celestone to determine whether the intervention is non-inferior for the primary outcome of a composite of perinatal mortality or substantial morbidity. please note: based on health canada's' guidance the study phase is 'other: off-label use'. however, on the clincaltrial.gov record, 'phase 4' is selected as this is the most relevant phase and there is no option to select 'other'. please note: mcmaster university, canada is the canadian regulatory sponsor and overall sponsor, and the university of adelaide australia is the australian sponsor.

Eligibility criteria:
inclusion criteria: 1. pregnant people, aged 18 to 55 years old, at risk of preterm birth with a singleton or twins between 22 weeks and 0 days and \<34 weeks and 6 days gestation who have received only a single dose of celestone within 24 hours 2. capable of giving informed, written consent. exclusion criteria: 1. contraindication to corticosteroids 2. systemic corticosteroids for medical conditions during the pregnancy (e.g. lupus, severe asthma, covid, etc). 3. previous participation in this trial (in a previous pregnancy) 4. known severe/life-threatening fetal or pregnant patient condition (e.g. fetal congenital/chromosomal abnormality) 5. demise of one or more fetuses after 14 weeks and 0 days

Keywords: premature birth preterm birth obstetric labour betamethasone betamethasone valerate betamethasone-17,21-dipropionate betamethasone benzoate betamethasone sodium phosphate anti-inflammatory agents glucocorticoids hormones hormones, hormone substitutes and hormone antagonists physiological effect of drugs anti-asthmatic agents respiratory system agents